Ignite Creation Date:
2025-12-25 @ 12:58 AM
Ignite Modification Date:
2026-06-15 @ 5:53 PM
Study NCT ID:
NCT03047993
Status:
COMPLETED
Last Update Posted:
2024-05-14
First Post:
2017-02-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Acute Myeloid Leukemia With Multilineage Dysplasia | View |
| None | Blasts 20-30 Percent of Bone Marrow Nucleated Cells | View |
| None | Blasts 20-30 Percent of Peripheral Blood White Cells | View |
| None | Chronic Myelomonocytic Leukemia | View |
| None | High Risk Myelodysplastic Syndrome | View |
| None | IPSS Risk Category Intermediate-2 | View |
| None | Myelodysplastic Syndrome | View |
Keywords: